Form 4: Kalaris Therapeutics Executive Acquires Stock Options
SEC Form 4 Filing
Brett R. Hagen, Chief Accounting Officer of Kalaris Therapeutics, Inc., reports the acquisition of stock options.
Summary
- On April 10, 2025, Brett R. Hagen, the Chief Accounting Officer of Kalaris Therapeutics, Inc., acquired stock options for 50,262 shares of common stock.
- The exercise price of the options is $7.31 per share.
- The options vest over four years, with 25% vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, contingent upon continuous service.
- The options expire on April 9, 2035.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The grant itself is a positive sign of incentivization, but the filing is routine.
Positives
- The acquisition of stock options by a key executive could signal confidence in the company's future performance.
Future Outlook
The vesting schedule indicates a long-term commitment from the executive, aligning their interests with the company's performance over the next four years.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
- The vesting schedule of four years with a one-year cliff (25% vesting after one year) is a typical arrangement.
- The number of shares granted and the exercise price would need to be compared to similar companies of Kalaris Therapeutics' size and stage to determine if it is in line with industry standards.
Stakeholder Impact
- The stock option grant aligns the executive's interests with those of the shareholders, potentially encouraging actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 04/10/2025 | Date of the stock option grant. |
| 03/18/2026 | Date when 25% of the options vest. |
| 04/09/2035 | Expiration date of the stock options. |
| 04/11/2025 | Date of signature on the Form 4 filing. |
Keywords
stock options, Kalaris Therapeutics, Form 4, executive compensation, Brett R. Hagen, Chief Accounting Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.